Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal

It is a hybrid medicine of Adriamycin, but available in a pegylated liposomal formulation
01 Sep 2022
Anticancer agents & Biologic therapy

On 21 July 2022, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product doxorubicin hydrochloride (Celdoxome pegylated liposomal), intended for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma.

The applicant for this medicinal product is YES Pharmaceutical Development Services GmbH.

Celdoxome pegylated liposomal will be available as a 2 mg/ml concentrate for dispersion for infusion. The active substance of Celdoxome pegylated liposomal is doxorubicin hydrochloride, a cytotoxic agent (ATC code: L01DB01) that inhibits DNA, RNA and protein synthesis.

Celdoxome pegylated liposomal is a hybrid medicine of Adriamycin which has been authorised in the EU since 24 October 1979. Celdoxome pegylated liposomal contains the same active substance as Adriamycin, but is available in a pegylated liposomal formulation. Studies have demonstrated the satisfactory quality of Celdoxome, and its bioequivalence to the reference product Caelyx, which contains doxorubicin hydrochloride in a pegylated liposomal formulation and was chosen as comparator.

The full indication is:

Celdoxome pegylated liposomal is indicated in adults: 

  • As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
  • For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
  • In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
  • For treatment of AIDS-related Kaposi’s sarcoma in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.
    Celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second-line chemotherapy in patients with AIDS-related Kaposi’s sarcoma with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Celdoxome pegylated liposomal should only be administered under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Hybrid applications rely in part on the results of pre-clinical tests and clinical studies for a reference product and in part on new data.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.